OXB has confirmed its manufacturing and supply partnership with Aura Biosciences to support the late-stage development of belzupacap sarotalocan (bel-sar), an investigational treatment for patients with ocular cancers. The partnership will help Aura advance the candidate through Phase 3 clinical development and prepare for potential future commercial production.
The collaboration, established earlier in 2026, focuses on manufacturing support for Aura’s lead virus-like drug conjugate (VDC) candidate, bel-sar. The treatment is being developed as a potential new option for patients with eye cancers.
Under the agreement, OXB will provide manufacturing and development support through its facilities in Bedford, Massachusetts, and Durham, North Carolina. The Bedford site will support process and analytical development, while the Durham facility will handle commercial-scale viral vector manufacturing.
OXB has already started the technical transfer process to prepare for process performance qualification (PPQ) and future commercial production. These activities are designed to ensure that the manufacturing process is reliable and ready to support late-stage clinical development, potential regulatory submissions and commercialisation.
The Durham facility is FDA-approved for commercial-scale manufacturing and offers both drug substance production and fill-and-finish capabilities at the same location. This will help support Aura’s manufacturing requirements as bel-sar moves closer to potential regulatory approval.
The partnership also marks OXB’s expansion into virus-like drug conjugate manufacturing, an area that complements its existing expertise in viral vector development and production.
OXB brings more than 30 years of experience in viral vector process development, analytical services and Good Manufacturing Practice (GMP) manufacturing. The company has supported several cell and gene therapy programmes from early development through clinical and commercial stages.
Dr. Sebastien Ribault, Chief Business Officer of OXB, said that a reliable and well-established manufacturing process will be important as Aura advances bel-sar through Phase 3 development. He added that OXB’s experience and commercial-scale manufacturing capabilities in Durham will support the programme’s future requirements.
For Aura Biosciences, the partnership is an important step in strengthening its manufacturing capabilities as it prepares for the next stages of bel-sar development.
The collaboration highlights the growing role of specialised contract development and manufacturing organisations (CDMOs) in supporting biotechnology companies as their drug candidates move into late-stage clinical trials and potential commercial production.